Shows & Panels
- The 2014 Big Picture on Cyber Security
- AFCEA Answers
- Ask the CIO
- Building the Hybrid Cloud
- Connected Government: How to Build and Procure Network Services for the Future
- Continuing Diagnostics and Mitigation: Discussion of Progress and Next Steps
- Federal Executive Forum
- Federal Tech Talk
- The Future of Government Data Centers
- The Future of IT: How CIOs Can Enable the Service-Oriented Enterprise
- The Intersection: Where Technology Meets Transformation
- Maximizing ROI Through Data Center Consolidation
- Moving to the Cloud. What's the best approach for me
- Navigating Tough Choices in Government Cloud Computing
- The New Generation of Database
- Satellite Communications: Acquiring SATCOM in Tight Times
- Targeting Advanced Threats: Proven Methods from Detection through Remediation
- Transformative Technology: Desktop Virtualization in Government
- The Truth About IT Opex and Software Defined Networking
- Value of Health IT
- Air Traffic Management Transformation Report
- Cloud First Report
- General Dynamics IT Enterprise Center
- Gov Cloud Minute
- Government in Technology Series
- Homeland Security Cybersecurity Market Report
- National Cybersecurity Awareness Month
- Technology Insights
- The Cyber Security Report
- The Next Generation Cyber Security Experts
Shows & Panels
Breast cancer drug on the FDA chopping block
Monday - 6/20/2011, 12:17pm EDT
Kathy Stewart, wtop.com
WASHINGTON -- The battle over a breast cancer drug will be heating up at the end of the month after the Federal Drug Administration banned its use.
In 2008, Avastin -- typically taken to treat kidney and colon cancer -- had been fast-tracked to also treat breast cancer. But after the drug's maker, Genentech, completed its third clinical trial, the FDA decided to pull the plug.
Dr. Frederick Tucker, a Fredericksburg oncologist, says the drug simply did not work.
He says the best Genentech could claim is that "Avastin didn't make patients worse." It also did not help them live longer or better while taking the medication.
If Genentech fails to reverse the FDA's decision, the company could lose between $500 million and $1 billion, says Tucker.
A new round of hearings is set for June 28 and 29.
Avastin has already been banned in England for breast cancer patients.
WTOP's Kathy Stewart contributed to this report. Follow WTOP on Twitter.
(Copyright 2011 by WTOP. All Rights Reserved.)